Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genprex Inc (GNPX)
NASDAQ:GNPX
Genprex (GNPX) Stock Price & Analysis
530 Followers
GNPX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.77 - $31.00
Previous Close$1.86
Volume15.37K
Average Volume (3M)103.77K
Market Cap
$3.90M
Enterprise Value-$4.31M
Total Cash (Recent Filing)$8.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Aug 13, 2019EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.18
Shares Outstanding2,098,698
10 Day Avg. Volume43,108
30 Day Avg. Volume103,772
Standard Deviation0.66
R-Squared0.00179
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)0.37
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$10.00Price Target Upside437.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Genprex News
PremiumCompany Announcements
Genprex Issues Shareholder Letter and Corporate Update
PremiumCompany Announcements
Genprex Annual Meeting Decisions: Director, Audits, and Compensation
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesReqorsa is expected to have multiple clinical milestones in three oncology programs of lung cancer.
Clinical Program ProgressThree clinical programs are underway evaluating Reqorsa in combination with other treatments for different stages and types of lung cancer.
Regulatory DesignationsReqorsa has been granted Orphan Drug and Fast Track designations in combination with Tecentriq for extensive-stage small cell lung cancer.
Bears Say
Capital RequirementsThe company had $8.2M in cash at the end of March 2024 and would need to raise additional capital within the next 12 months to fund ongoing operations.
Financial PerformanceNet loss totaled $6.0M in the first quarter of 2024.
LeadershipThe company recently experienced a leadership change following the sudden passing of its co-founder, President, Chairman, and CEO.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GNPX FAQ
What was Genprex Inc’s price range in the past 12 months?
Genprex Inc lowest stock price was $1.77 and its highest was $31.00 in the past 12 months.
What is Genprex Inc’s market cap?
Currently, no data Available
When is Genprex Inc’s upcoming earnings report date?
Genprex Inc’s upcoming earnings report date is Aug 13, 2019 which is 1812 days ago.
How were Genprex Inc’s earnings last quarter?
Genprex Inc released its earnings results on May 15, 2019. The company reported -$0.141 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.141.
Is Genprex Inc overvalued?
According to Wall Street analysts Genprex Inc’s price is currently Undervalued.
Does Genprex Inc pay dividends?
Genprex Inc does not currently pay dividends.
What is Genprex Inc’s EPS estimate?
Genprex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genprex Inc have?
Genprex Inc has 2,098,698 shares outstanding.
What happened to Genprex Inc’s price movement after its last earnings report?
Genprex Inc reported an EPS of -$0.141 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Genprex Inc?
Currently, no hedge funds are holding shares in GNPX
---
Genprex Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (437.63% Upside)
$10.00 (437.63% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.88%
12-Months-Change
Fundamentals
Return on Equity
-202.83%
Trailing 12-Months
Asset Growth
-46.12%
Trailing 12-Months
Company Description
Genprex Inc
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
---
GNPX Stock 12 Month Forecast
Average Price Target
$10.00
▲(437.63% Upside)
Technical Analysis
Best Analysts Covering GNPX
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-34.23%
reiterated a buy rating 2 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.23% per trade.
---